AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Innoviva, Inc. Director's Dealing 2021

May 24, 2021

32090_dirs_2021-05-24_ec3a6e2b-5e69-4f8f-a445-0cbca729b260.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Innoviva, Inc. (INVA)
CIK: 0001080014
Period of Report: 2021-05-20

Reporting Person: GLAXOSMITHKLINE PLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-20	Common Stock	S	32005260	$12.25	Disposed	0	Indirect

Footnotes

F1: Common stock sold pursuant to a share repurchase agreement by and between Glaxo Group Limited ("GGL"), an indirect wholly owned subsidiary of the Reporting Person, and Innoviva, Inc. (the "Issuer") dated as of May 20, 2021.

F2: Common Stock was held of record by GGL, an indirect wholly owned subsidiary of the Reporting Person.